

증례로 보는 ILD치료의 실제

Organizing pneumonia 감별진단과 치료

Byoung Soo Kwon

Division of Pulmonary and Critical Care Medicine


Department of Internal Medicine, Seoul National University Bundang Hospital



Disclosure of Conflict of Interest

- None to declare

Classification of ILDs



Eur Respir Rev 2018; 27: 180076

History of terminology : BOOP vs. COP

- Alveolar disease -> cryptogenic organizing pneumonia (COP)
- Airway disorder -> obliterative bronchiolitis (OB)
- COP - bronchiolitis interstitial pneumonia (BIP)
Bronchiolitis obliterans organizing pneumonia (BOOP)


Eur Respir Rev 2021; 30: 210094

COP is,

- **acinar-centric disorder** rather than airway disease!
- The term BOP should be discarded in the medical literature



Epidemiology

- 1.10 cases per 100,000
- 6.7 cases per 100,000



Tuberc Respir Dis 2009;66:141-151
N Engl J Med 2022;386:1058-69

Lung repair, two-edged sword



N Engl J Med 2022;386:1058-69

Causes of organizing pneumonia

TABLE 1 Conditions associated with organising pneumonia (OP)[#]

Connective tissue disorders
Hypersensitivity pneumonitis (acute)
Adverse drug reactions
Bone marrow, stem cell or solid organ transplantation
Infection
Airway diseases complicated by infection
Airway obstruction (distal changes)
Inhalation injury
Aspiration syndromes
Chronic eosinophilic pneumonia
Radiation pneumonitis
Inflammatory bowel disease
Neoplasms and myeloproliferative disorders
Organising diffuse alveolar damage
Coexistent with pathologic changes of IIP (e.g. UIP or NSIP)
Acute exacerbation of IPF (OP lesions superimposed on chronic UIP pattern)
Proximal bronchial obstruction (OP found distal to focus of obstruction)
Miscellaneous
Immunodeficiency syndromes
Cryoglobulinemia
Granulomatosis with polyangiitis
Other vasculitis

vs.

cryptogenic OP

Eur Respir Rev 2021; 30: 210094


Clinical presentation

- Subacute, several weeks to months
- Symptoms
 - Dry cough
 - DOE
 - Fever
 - Influenza-like symptoms
 - Hemoptysis (rare)
- Infectious pneumonia do not have a response to antibiotics







Radiology of OP

- Pattern
 - Peripheral and multifocal GGO / consolidation, with or without air-bronchogram
 - Nodules (10-40%)
- Location
 - Unilateral / bilateral
 - Peribronchovascular
 - All lung zones (subpleural and lower lung zone distribution>)
- Others
 - Migratory opacities
 - Spontaneous regression
 - Reversed halo sign

Radiology of OP




Eur Radiol. 2021 Oct;31(10):7283-7294



Reversed halo (atoll) sign

- 60, Female



Diagnostic accuracy of HRCT

CT Finding	UIP (%)	BOOP (%)	DIP (%)	AIP (%)	NIPF (%)
Areas of ground-glass attenuation	97	100	100	100	100
Air-space consolidation	23	83	13	80	41
Honeycombing	71	13	39	30	26
Intralobular reticular opacities	97	71	78	70	93
Nodules	11	63	44	25	19
Zonal predominance					
Upper	0	4	0	10	4
Lower	71	48	83	25	74
Random	29	48	17	65	22
Anatomic distribution					
Peripheral	89	71	43	10	85
Peribronchovascular	3	17	0	5	19
Dorsal	0	25	0	10	11
Random	11	13	57	80	11

Disease	Correct Diagnosis*
UIP (<i>n</i> = 35)	25.0 (71)
BOOP (<i>n</i> = 24)	19.0 (79)
DIP (<i>n</i> = 23)	14.5 (63)
AIP (<i>n</i> = 20)	13.0 (65)
NIPF (<i>n</i> = 27)	2.5 (9)
Total (<i>n</i> = 129)	74.0 (57)

Radiology. 1999 May;211(2):555-60

BAL: to rule out infection & eosinophilia

Disease	n
COP	28
Chronic eosinophilic pneumonia	2
Metastatic kidney adenocarcinoma	1
Primary large cell anaplastic lymphoma	1
Tuberculosis	1
Bronchoalveolar carcinoma	2
Total	35

Predefined criteria

BAL

lymphocytosis, more than 25%, plus
foamy macrophage >20%
neutrophils > 5%
eosinophil 2 - 25%

TBLB

bud of granulation tissue within small airway / alveoli
preservation of alveolar architecture

Diagnostic test	Pts n	True +ve	True -ve	False +ve	False -ve	Specificity	Sensitivity	PPV	NPV	Accuracy
BAL	34	17	4	3	10	0.57	0.63	0.85	0.29	0.62
TBLB	32	16	6	1	9	0.86	0.64	0.94	0.40	0.69

Eur Respir J, 1996, 9, 2513-2516

BAL: to rule out infection & eosinophilia

- French collaborative group
 - Histopathologic diagnosis
 - Clinical / radiological features
 - Absence of identifiable causes
 - Treated by corticosteroids
- 48 cases
 - Relapse (R group)
 - Absence of relapse (NR group)

	n	NR Group	% pred	n	R Group	% pred	p Value
BAL							
n		14		20			
Total cell count, cell/ μ l		417 \pm 310		341 \pm 235			NS
Macrophages, %		54 \pm 25		53 \pm 28			NS
Lymphocytes, %		32 \pm 21		25 \pm 18			NS
Neutrophils, %		9 \pm 9		13 \pm 16			NS
Eosinophils, %		5 \pm 10		8 \pm 13			NS
Pulmonary function tests							
FEV ₁ , L	15	1.8 \pm 0.6	71 \pm 22	17	1.8 \pm 0.6	79 \pm 18	NS
FVC, L	15	2.4 \pm 0.7	75 \pm 20	17	2.4 \pm 0.7	81 \pm 16	NS
FEV ₁ /FVC, %	15	74 \pm 11	94 \pm 14	17	75 \pm 12	97 \pm 14	NS
TLC, L	12	4.6 \pm 1.3	85 \pm 13	14	4.5 \pm 1.4	84 \pm 15	NS
RV, L	12	2.0 \pm 0.8	101 \pm 30	14	1.7 \pm 0.7	96 \pm 36	NS
T _{LCO} , % pred	9		74 \pm 21	13		90 \pm 25	NS
Resting Pa _{O₂} , mm Hg	16	68 \pm 11		15	72 \pm 8		NS

Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):571-7

BAL cellular pattern in ILDs

a. Disorders associated with increased percentage of specific BAL cell types

Lymphocytic cellular pattern	Eosinophilic cellular pattern	Neutrophilic cellular pattern
>15% lymphocytes	>1% eosinophils	>3% neutrophils
Sarcoidosis Nonspecific interstitial pneumonia (NSIP) Hypersensitivity pneumonitis Drug-induced pneumonitis Collagen vascular diseases Radiation pneumonitis Cryptogenic organizing pneumonia (COP) Lymphoproliferative disorders	Eosinophilic pneumonias Drug-induced pneumonitis Bone marrow transplant Asthma, bronchitis Churg-Strauss syndrome Allergic bronchopulmonary aspergillosis Bacterial, fungal, helminthic, <i>Pneumocystis</i> infection Hodgkin's disease	Collagen vascular diseases Idiopathic pulmonary fibrosis Aspiration pneumonia Infection: bacterial, fungal Bronchitis Asbestosis Acute respiratory distress syndrome (ARDS) Diffuse alveolar damage (DAD)

A lymphocyte differential count $\geq 25\%$ suggests granulomatous disease (sarcoidosis, hypersensitivity pneumonitis, or chronic beryllium disease), cellular nonspecific interstitial pneumonia, drug reaction, lymphoid interstitial pneumonia, cryptogenic organizing pneumonia, or lymphoma.


Am J Respir Crit Care Med 2012; 185, 9, 1004-14

47/Female

- 주소: 발열
- 현병력: 1달 전 부터 지속되는 마른 기침, 열감으로 연고지 병원 내원, COVID-19 PCR 시행, 음성이었고, 이후 기침은 호전되지 만 발열 지속 및 호흡곤란 발생, 체중감소를 주소로 COVID-19 배제 위해 감염내과 입원함.
- 체중감소 (+), -3kg/1달
- Initial laboratory tests
 - CBC: 8250 - 12.2 - 501K
 - CRP: 6.44
 - ESR: 103

47/Female

R PA



BAL fluid analysis

RBC: 130 / ul

WBC: 160 / ul

Differential counts (%)


Macrophage : 51%

Segmented neutrophil : 8%

Lymphocyte : 30%

Eosinophil: 11%


CD4 44%, CD8 48%



25/Female

- 주소: 호흡곤란
- 현병력: 1달 전 기침 발생하였고, 점차 악화 추세 및 mMRC grade 2 으로 폐렴에 준하여 연고지병원에서 항생제 치료 받았으나 증상 지속되어 방문.
- Initial laboratory tests
 - CBC: 5420 (eos. 9.1%) - 13.3 - 345K
 - CRP: 8.1

25/Female



BAL fluid analysis

RBC: 6250 / ul

WBC: 970 / ul

Differential counts (%)


Macrophage : 38%

Segmented neutrophil : 0%




Lymphocyte : 20%

Eosinophil: 42%

CD4 27%, CD8 64%






COP vs. CEP



Histopathology of OP

- Proliferation of granulation tissue buds
- Preserved underlying lung architecture



Eur Respir Rev 2021; 30: 210094

N Engl J Med 2022;386:1058-69

RadioGraphics 2013; 33:1951-1975


Histopathology of OP

- Can be managed without histopathological confirmation
- Biopsy is recommended,
 - Clinical follow-up is not consistent with the diagnosis of COP
 - Absence of typical waxing/waning image
 - Need to be ruled out of vasculitis
- Biopsy modalities
 - Core needle biopsy
 - TBLB
 - TBLC
 - SLBx


Eur Respir Rev 2021; 30: 210094

Tissue acquisition

VATS




TBLC



TBLB






PCNBx




Tissue confirmation

- The best modalities ? Ongoing debate



*World Journal of Surgery volume 44, pages1892-1897 (2020)
Chest 1991; 100: 959-62*

Diagnostic algorithm



Eur Respir Rev 2021; 30: 210094

Treatment

권고사항


- 특발성기질화폐렴(COP) 치료는 스테로이드를 권장한다(근거수준: 전문가 의견, 권고수준: 강함).
- 특발성기질화폐렴(COP) 환자에서 스테로이드 단독 치료가 효과가 없는 경우 azathioprine이나 cyclophosphamide, 그리고 cyclosporin과 같은 면역억제제와 병합치료를 하지 않을 것을 고려한다(근거수준: 전문가 의견, 권고수준: 약함).

Treatment

- Spontaneous improvement (<10%) vs. empirical treatment
 - Systemic glucocorticoid, 0.5 - 1mg / kg (max. 60mg) up to 6 -12 mos.
- Cytotoxic agents
 - Azathioprine
 - Cyclophosphamide
- Mycophenolate mofetil

41 / Female

- 수술전 평가로 시행한 흉부 엑스레이 이상소견으로 방문
- 호흡기증상: 무




Treatment

- GERM"O"P protocol
 - 0 - 4 wk : 0.75mg/kg prednisolone
 - 4 - 8 wk : 0.5mg/kg
 - 8 - 12wk : 20mg
 - 12 - 18wk: 10mg
 - 18 - 24wk: 5mg

Ex. 60kg


45mg -> 30mg -> 20mg -> 10mg -> 5mg -> off




Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):571-7

Treatment related side effects

- Linear & threshold pattern



Cushingoid, ecchymosis, leg edema, mycosis, sleep disturbance




<5: cataract
5 - 7.5: epistaxis, weight gain
7<: depression, glaucoma, high BP

Ann Rheum Dis 2009;68:1119-1124

Prognosis


- Generally excellent
 - Clinical improvement within 2-3 days



- 5yr survival rate > 90%

Prognosis



- Relapse is relatively frequent : 13 - 58%
 - Delayed initiation of treatment (> 2months after diagnosis)
 - Rapid tapering or early discontinuation
 - Severe disease
 - Traction bronchiectasis / fibrosis
- **Unusual cases of relapse**
 - while on medium doses of steroids
 - >18 months following the initial onset of COP
- Treatment
 - Resuming or increasing steroids
- Morbidity / mortality -




Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):571-7

65 / Female

- 주소: 호흡곤란
- 현병력: 3개월 전 호흡곤란으로 연고지 병원 입원, 호산구성 폐렴으로 판단하고 2개월 간 스테로이드 투약 후 흡입스테로이드 유지 중으로, 이후 폐렴 재발하여 2차 의견 청취 위해 방문



65 / Female






BAL

RBC (/ μl)	340
WBC (/ μl)	140

Differential count (%)	Total count:
Macrophage	79
Mesothelial cell	0
Segmented neutrophil	2
Lymphocyte	19
Eosinophil	0
Basophil	0
Tumor cell	0

65 / Female




65 / Female



ANA, cytoplasmic, 1:160
ANCA, MPO/PrIII, negative <0.1

Relapse of COPD
→ prednisolone



Disease behavior

Reversible and self-limited

RB-ILD

Reversible with risk of progression

cNSIP, some fNSIP, DIP, COP

Stable with residual disease


Some fNSIP

Progressive, irreversible, with potential stabilization

Some fNSIP

Progressive, irreversible despite therapy

IPF, some fNSIP



Am J Respir Crit Care Med 2013, 88, 733-748
Curr Med Res Opin 2019 Nov;35(11):2015-2024





Serial CT findings - Samsung Medical Center

Parameter	Initial CT		Follow-Up CT	
	No. (%) of Patients	Average Extent (%)	No. (%) of Patients	Average Extent (%)
Pattern				
Consolidation	17 (77)	27	1 (5)	20
Ground-glass opacification	19 (86)	33	16 (72)	21
Nodule	7 (32)	10	1 (5)	10
Reticulation	4 (18)	10	11 (50)	12
Honeycombing	0	0	2 (9)	8
Distribution				
Lower lung predominance	12 (55)	NA	10 (45)	NA
Subpleural	9 (41)	NA	8 (36)	NA
Peribronchovascular	5 (23)	NA	4 (18)	NA

- Complete disappear: 6
- Decreased in extent: 15
- Not changed: 1



AJR 2010; 195:916 - 92 2



Serial CT findings - Samsung Medical Center



43/Female


- 2달간 기침, 가래, mMRC grade 1 호흡곤란으로 연고지병원 내원, BAL & TBLB 시행 후 내원함.
- 외부자료
 - BAL - lymphocytes 93%
 - Lung, "left lower lobe", transbronchial lung biopsy :
Non-neoplastic lung parenchyma
with 1) chronic inflammation
2) interstitial fibrosis
3) fibroblastic plugs
4) no granuloma and no fungal organism
consistent with Organizing pneumonia






1st relapse

R PA



43/Female

- 재발에 대해 1년간 스테로이드 투약 종료 후 관절통, mechanic's hands 발생
 - RF / Anti - ccp: negative
 - FANA Titer (1:40): Positive, Multiple nuclear dots



→ 류마티스내과: DM specific skin, muscle involvement 는 뚜렷하지 않아 undifferentiated 로 추이 관찰하며 workup 여부 결정

Secondary op vs. COP

Variable	OP	COP	Secondary OP	Variable (No. COP/Secondary OP)	OP ± SD	COP ± SD	Secondary OP ± SD	P Value
Chest radiograph				Macrophages (27/5)	43.94 ± 14.28	44.30 ± 14.28	42.00 ± 15.81	NS
Consolidation	50 (82.0)	33 (82.5)	17 (81.0)	Lymphocytes (27/5)	18.84 ± 12.19	16.07 ± 9.025	33.80 ± 17.06	.002
Bilateral	35 (68.6)	24 (72.7)	11 (61.1)	Neutrophils (27/5)	26.09 ± 16.63	27.52 ± 16.36	18.40 ± 17.78	NS
Diffuse reticular	7 (11.5)	4 (10.0)	3 (14.3)	Eosinophils (27/5)	10.19 ± 9.50	11.22 ± 9.79	4.60 ± 5.50	NS
Masslike lesion	5 (8.2)	4 (10.0)	1 (4.8)	Mast cells (27/5)	2.28 ± 2.59	2.52 ± 2.68	1.00 ± 1.73	NS
Pleural effusion	7 (11.5)	3 (7.5)	4 (19.0)	Lymphocytes > 20%	14 (43.8)	10 (37)	4 (80)	NS
Cavitation	1 (1.6)	1 (2.5)	0 (0)					
Migratory lesions	7 (11.5)	7 (17.5)	0 (0)					
CT scan								
Consolidation	49 (80.3)	31 (77.5)	18 (85.7)					
Bilateral	36 (73.5)	25 (80.6)	11 (61.1)					
Diffuse reticular	6 (9.8)	4 (10)	2 (9.5)					
Masslike lesion	5 (8.2)	4 (10)	1 (4.8)					
Pleural effusion	7 (11.5)	3 (7.5)	4 (19.0)					
Cavitation	1 (1.6)	1 (2.5)	0 (0)					
Migratory lesions	7 (11.5)	7 (17.5)	0 (0)					

Chest. 2011 Apr;139(4):893-900

Secondary op vs. COP

Treatment	OP	COP	Secondary OP
Corticosteroids	41 (77.4)	30 (81.1)	11 (68.8)
Macrolides	3 (5.7)	2 (5.4)	1 (6.3)
No treatment	9 (17)	5 (13.5)	4 (25.0)
Relapse	17 (37.8)	13 (38.2)	4 (36.4)
1-y mortality	5 (9.4)	2 (5.3)	3 (20)
In-hospital mortality	3 (5.7)	1 (2.6)	2 (13.3)

Chest. 2011 Apr;139(4):893-900

COP vs. CTD-related OP

Outcomes	CTD-OP	COP	P-value
Improvement	20 (83.3)	69 (90.8)	0.309
Complete recovery	5 (20.8)	35 (46.1)	0.028
Recurrence ^a	8 (40.0)	14 (20.3)	0.072
Progression	3 (12.5)	5 (6.6)	0.394
Rapid progression	1 (4.2)	5 (6.6)	1.000
Stable	1 (4.2)	2 (2.6)	0.565
Overall death	3 (12.5)	20 (26.3)	0.265
Disease-related death	3 (12.5)	11 (14.5)	0.253
Survival, mean (95% CI), months	117.1 (95.6–138.6)	97.6 (82.9–112.4)	0.214
Mortality			
1 year	2 (8.7)	6 (8.1)	0.214
3 years	2 (8.7)	8 (11.6)	
5 years	3 (18.9)	11 (19.3)	

Rheumatology 2011;50:932938

COP vs. CTD-related OP


	Total	Type	
		COP	CTD-OP
Patients	166	131 (78.9)	35 (21.1)
Age	57.2 ± 10.9	57.1 ± 10.9	58.9 ± 9.4
Sex			
Male	55 (33.1)	41 (35.9)	10 (28.6)
Female	111 (66.9)	84 (64.1)	25 (71.4)
Treatment response			
CR	40 (24.1)	37 (28.2)	3 (8.5)
PR	39 (23.5)	36 (27.4)	3 (8.5)
Stable	15 (9.1)	14 (10.7)	1 (2.8)
Progression	19 (11.4)	10 (7.6)	9 (25.7)
Relapse	53 (31.9)	34 (26.1)	19 (54.3)

	Univariate		Multivariate			
	HR	<i>p</i>	95% CI	HR	<i>p</i>	95% CI
RD						
Bronchiectasis	4.38	< 0.001	2.1–94.	3.59	0.002	1.6–7.9
Con > 10%	2.46	0.015	1.2–5.1	2.27	0.04	1.0–4.9
CTD-OP	4.19	0.024	1.2–14.5	4.31	0.027	1.1–15.7
Relapse						
Con > 10%	2.86	0.008	1.3–6.2	2.54	0.028	1.1–5.9
Total > 25%	2.77	0.015	1.2–6.3			
CTD-OP	6.79	< 0.001	2.5–18.6	6.42	< 0.001	2.3–18.1

European Radiology 2020;30;2722-30

Take home message

- Organizing is a **process of lung repair** after injury.
- Symptoms (dry cough, dyspnea) are **subacute or chronic**.
- On HRCT, **bilateral consolidation with perilobular / perivascular distribution** is the most common finding.
- Proliferation of **granulation tissue buds** is the key histopathologic feature.
- Although no RCTs have been performed, **systemic glucocorticoid** is the preferred treatment.
- **A significant number of patients have relapses**, although these will show a favorable response to corticosteroid therapy.
- In addition, a small number of patients **may develop recurrent/progressive disease**; therefore, a thorough evaluation to detect secondary OP, especially CTD-ILDs, is required.



Thomas Henry Huxley

“We are nothing more than a small island floating in the middle of an endless sea of ignorance that cannot be explained.




It is the human duty to expand the island little by little with each generation”

Thank you for your attention

Email: bskwon82@snuh.org



Backup #1

- March ~ May, 2020, university Giessen, Germany
- SARS-CoV-2 positivity: 38 patients
- ICU admission: 24 patients
- Development of OP: 3 patients (12.5%)





Thorax 2020;0:1-4

Backup #2






Infect Chemother. 2022 Mar;54(1):208-212

Backup #3



Ann Am Thorac Soc Vol 18, No 5, pp 799-806

Backup #3




Lung Function	Before Treatment	After Treatment	Mean Difference (95% CI)	P Value
FVC, L	3.07 ± 1.12	3.36 ± 1.11	0.42 (0.28–0.56)	0.014
FVC, %	86.8 ± 18.5	99.2 ± 19.1	9.63 (4.49–14.7)	0.004
T _{LCO} , SI	5.56 ± 2.56	7.05 ± 2.42	1.72 (1.18–2.25)	<0.001
T _{LCO} , %	59.7 ± 21.1	82.6 ± 15.7	22.3 (14.1–32.5)	<0.001
KCO, T _{LCO} /L	1.25 ± 0.34	1.83 ± 0.36	0.27 (0.16–0.37)	0.025
KCO, %	82.9 ± 28.8	104.3 ± 24.0	19.9 (9.72–30.1)	0.002

Ann Am Thorac Soc Vol 18, No 5, pp 799-806

80/Female

- 주소: 호흡곤란
- 현병력: 3주 전 COVID-19 확진되어 무증상, 자가 격리. 1주 전 부터 전신 기력 저하 및 poor oral intake, 1일전 호흡곤란으로 응급실 내원
- 과거력: follicular lymphoma (- 2021.10) -> mCR
- Initial laboratory tests
 - CBC: 3210 - 10.0 - 158K
 - CRP: 21.12





64 / Male



- Lung, right lower lobe, wedge resection :
- Organizing pneumonia ("RLL wedge 1" and "RLL wedge 2")
- 1) fibroblastic plugs
 - 2) alveolar macrophage collection
 - 3) subpleural fibrosis ("RLL wedge 1")
 - 4) bronchoalveolar metaplasia ("RLL wedge 1")

64 / Male




Variants

- Focal organizing pneumonia (<15%)
- Fulminant disease
- Cicatricial organizing pneumonia
- Acute fibrinous organizing pneumonia (AFOP)


58/Male

- 주소: 호흡곤란
- 현병력: 평소 mMRC grade 1로 유지되던 자로, 내원 4일 전 기침, 호흡곤란 악화 (1 ->3-4), 발열로 응급실 내원, ILD 급성악화로 입원함.
- Initial laboratory tests
 - CBC: 10170 - 13.0 - 256K
 - CRP: 14.00
 - ABGA: 7.466 - 34.8 - 92.1 - 25.1 (nasal prong 3L/min)




58/Male

- Treatment
 - Steroid pulse #2
 - prednisolone
 - On nintedanib




AFOP - SNUBH

- Rare histologic pattern of IIP



BMC Pulmonary Medicine (2022) 22:56

AFOP - SNUBH



BMC Pulmonary Medicine (2022) 22:56